Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1-22. (Cancelled)

23. (Currently amended) A method for inhibiting replication of a virus of an HIV strain that is resistant to a chemotherapeutic agent selected from Delavirdine, Nevirapine, Efavirenz, Trovirdine, AZT, and MKC-442, the method comprising:

contacting the resistant virus with an amount of a compound effective to inhibit replication of the virus,

wherein the compound is of the formula:



wherein x is: 2,5-OMe or *o*-F.

24. (Cancelled)

25. (Previously presented) A method for inhibiting replication of an HIV having a mutation of an amino acid at position 106 or 183 of reverse transcriptase, the method comprising:

contacting the HIV with an amount of a compound effective to inhibit replication of the HIV,

wherein the compound is of the formula:



wherein x is: 2,5-OMe or *o*-F.

26. (Previously presented) A method for inhibiting replication of an HIV having one or more of the following amino acid substitutions in reverse transcriptase : L100I, K103N, V106A, E138K, Y181C, or Y188H; the method comprising:

contacting the HIV with an amount of a compound effective to inhibit replication of the HIV,

wherein the compound is of the formula:



wherein x is: 2,5-OMe or *o*-F.

27. (Previously presented) A method for inhibiting replication of a virus of an HIV strain that is resistant to a non-nucleoside inhibitor-resistant strain of HIV; the method comprising

contacting the resistant virus with an amount of a compound effective to inhibit replication of the virus,

wherein the compound is of the formula:



wherein x is: 2,5-OMe or *o*-F.

28. (Previously presented) A method of inhibiting replication of a virus of an HIV strain selected from the group consisting of RT-MDR, HIV A17, and HIV A17 variant; the method comprising:

contacting the virus with an amount of a compound effective to inhibit replication of the virus

wherein the compound is of the formula:



wherein x is: 2,5-OMe or *o*-F.

29. (Previously presented) The method of claim 23, wherein the compound is



30. (Previously presented) The method of claim 25, wherein the compound is



31. (Previously presented) The method of claim 26, wherein said compound is



32. (Previously presented) The method of claim 27, wherein the compound is



33. (Previously presented) The method of claim 28, wherein the compound is



34. (Previously presented) The method of claim 23, wherein said compound is



35. (Previously presented) The method of claim 25, wherein the compound is



36. (Previously presented) The method of claim 26, wherein the compound is



37. (Previously presented) The method of claim 27, wherein the compound is



38. (Previously presented) The method of claim 28, wherein the compound is



39. (Previously presented) The method of claim 23, wherein the replication of the virus is inhibited within a human peripheral blood mononuclear cell.

40. (Previously presented) The method of claim 24, wherein the replication of the virus is inhibited within a human peripheral blood mononuclear cell.

41. (Previously presented) The method of claim 25, wherein the replication of the HIV is inhibited within a human peripheral blood mononuclear cell.

42. (Previously presented) The method of claim 26, wherein the replication of the HIV is inhibited within a human peripheral blood mononuclear cell.

43. (Previously presented) The method of claim 27, wherein the replication of the virus is inhibited within a human peripheral blood mononuclear cell.

44. (Previously presented) The method of claim 28, wherein the replication of the virus is inhibited within a human peripheral blood mononuclear cell.